Exenatide vs Prostamax
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- Half-Life
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 5 mcg, titrate to 10 mcg
- 10 mg per day
- Frequency
- Twice daily
- Daily for 10–30 days
- Key Benefits
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Side Effects
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Stacks With
- —
- —